Company profile: Kiadis Pharma
1.1 - Company Overview
Company description
- Provider of novel biopharmaceutical treatment options focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients, with three products in clinical development addressing high-unmet medical needs of terminally ill cancer patients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kiadis Pharma
Dune Medical
HQ: United States
Website
- Description: Provider of intraoperative, real-time cancer detection devices using proprietary tissue characterization technology, enabling surgeons and radiologists to detect cancer in real time with potential for broad diagnostic and therapeutic applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dune Medical company profile →
Exact Imaging
HQ: Canada
Website
- Description: Provider of 29 MHz micro-ultrasound imaging for real-time targeted prostate biopsies via the ExactVu system, offering high-resolution visualization and enhancements like ExactVu Micro Doppler. Solutions include PRI-MUS protocol for prostate cancer risk assessment, FusionVu for MRI-ultrasound alignment and targeting, and Cognitive Assist for cognitive fusion displaying MRI-identified lesions in real time.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exact Imaging company profile →
MaxiVAX
HQ: Switzerland
Website
- Description: Provider of clinical-stage cancer immunotherapies and cell-encapsulation delivery platforms, including MVX-ONCO-1 for recurrent/metastatic head and neck squamous carcinoma, Encapsulated Cell Technology for sustained, controlled protein delivery (e.g., low-dose anti-CTLA-4 in a colorectal cancer model), and MVX-ONCO-2, a second-generation personalized immunotherapy for advanced solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MaxiVAX company profile →
Peptomyc
HQ: Spain
Website
- Description: Provider of next-generation cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. Built on Dr. Soucek’s Omomyc research, the company’s lead candidate, OMO-103, is an Omomyc-derived therapeutic peptide designed to inhibit the deregulated Myc oncoprotein in many cancers to halt tumor growth and progression. Founded in December 2014.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Peptomyc company profile →
Mevion Medical Systems
HQ: United States
Website
- Description: Provider of innovative, safe, and effective radiation therapy solutions for the treatment of cancer, pioneering modern proton therapy systems and transforming advances in medical technology and science into practical clinical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mevion Medical Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kiadis Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kiadis Pharma
2.2 - Growth funds investing in similar companies to Kiadis Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kiadis Pharma
4.2 - Public trading comparable groups for Kiadis Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →